| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/06/2024 | 17:00 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 14/06/2024 | 15:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 06/06/2024 | 14:30 | GlobeNewswire Inc. | Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 03/06/2024 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 08/05/2024 | 15:25 | GlobeNewswire Inc. | LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 24/04/2024 | 21:25 | AllPennyStocks.com | Mixed Shelf Filing Gives Micro Cap Delayed Boost | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 27/03/2024 | 20:35 | AllPennyStocks.com | Biotech Steals The Show Following Pre-Clinical Data Announcement | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 27/03/2024 | 13:30 | GlobeNewswire Inc. | NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 21/03/2024 | 13:30 | GlobeNewswire Inc. | LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 27/02/2024 | 22:59 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 27/02/2024 | 14:30 | GlobeNewswire Inc. | Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/02/2024 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/01/2024 | 14:30 | GlobeNewswire Inc. | First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/11/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 09/11/2023 | 23:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/10/2023 | 20:51 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/10/2023 | 21:55 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/10/2023 | 21:47 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 09/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 06/10/2023 | 02:39 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/09/2023 | 22:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Appoints Bas van der Baan as President and Chief Executive Officer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 22/08/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 11/08/2023 | 22:20 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 01/08/2023 | 21:37 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:25 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:05 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 18/07/2023 | 14:00 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |